#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar
Tweet Content
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off